ASX Announcement

27 November 2026

Corrected Substantial Holder Notices – Wu Chun-Yi and Wu Yi-Chi

Cambium Bio Limited (ASX: CMB) (Company) attaches corrected Form 604 notices of change of interests of substantial holder given by Mr Wu Chun-Yi and Ms Wu Yi-Chi. The corrected notices replace the notices lodged on 19 November 2026.

The corrections relate to the date of change and the registered holder of the new shares. The 8,635,056 shares issued to Mr Wu and Ms Wu under the placement approved by shareholders at the Company's 2026 Annual General Meeting were issued on 18 November 2026 and registered in their own names, rather than with J P Morgan Nominees Australia Pty Limited as stated in the previous notices. Mr Wu's 5,448,000 previously held shares remain registered with J P Morgan Nominees Australia Pty Limited.

The combined voting power of Mr Wu and Ms Wu, as associates, is unchanged at 31.85%.

– ENDS –

About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialisation, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio

Authorisation & Additional Information

This announcement was authorised for release by the Board of Directors of Cambium Bio Limited.

For further information, please contact:
Company Secretary
Email: info@cambium.bio